title: Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.forename: Ciro
authors.initials: C
authors.lastname: Gallo
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D002986:Clinical Trials as Topic / Q000379:methods*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D023381:Endpoint Determination; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D009367:Neoplasm Staging; D018579:Patient Selection; D012107:Research Design